IFP Advisors Inc Increases Stock Position in TG Therapeutics, Inc. $TGTX

IFP Advisors Inc lifted its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 1.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 190,697 shares of the biopharmaceutical company’s stock after acquiring an additional 2,635 shares during the period. IFP Advisors Inc owned 0.12% of TG Therapeutics worth $6,874,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Ameritas Advisory Services LLC purchased a new position in shares of TG Therapeutics during the second quarter worth approximately $25,000. NBC Securities Inc. grew its position in shares of TG Therapeutics by 82,300.0% during the first quarter. NBC Securities Inc. now owns 824 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 823 shares during the last quarter. Golden State Wealth Management LLC grew its position in shares of TG Therapeutics by 100.0% during the first quarter. Golden State Wealth Management LLC now owns 866 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 433 shares during the last quarter. SVB Wealth LLC purchased a new position in shares of TG Therapeutics during the first quarter worth approximately $37,000. Finally, USA Financial Formulas purchased a new position in shares of TG Therapeutics during the first quarter worth approximately $57,000. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on TGTX. The Goldman Sachs Group upgraded shares of TG Therapeutics to a “hold” rating and set a $37.00 target price on the stock in a research report on Thursday, July 10th. Weiss Ratings reiterated a “hold (c-)” rating on shares of TG Therapeutics in a research report on Wednesday. HC Wainwright began coverage on shares of TG Therapeutics in a research report on Monday. They issued a “buy” rating and a $60.00 price objective on the stock. Finally, B. Riley lifted their price objective on shares of TG Therapeutics from $53.00 to $55.00 and gave the company a “buy” rating in a research report on Wednesday, September 17th. Four research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $49.00.

Insider Activity at TG Therapeutics

In other TG Therapeutics news, Director Sagar Lonial sold 20,852 shares of the business’s stock in a transaction on Thursday, September 11th. The shares were sold at an average price of $32.24, for a total transaction of $672,268.48. Following the sale, the director directly owned 94,061 shares in the company, valued at approximately $3,032,526.64. The trade was a 18.15% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 10.64% of the company’s stock.

TG Therapeutics Stock Performance

NASDAQ:TGTX opened at $34.97 on Friday. The firm has a market cap of $5.55 billion, a price-to-earnings ratio of 94.51 and a beta of 1.97. TG Therapeutics, Inc. has a 1-year low of $21.27 and a 1-year high of $46.48. The firm’s fifty day moving average price is $31.54 and its 200 day moving average price is $35.31. The company has a debt-to-equity ratio of 0.89, a current ratio of 3.86 and a quick ratio of 2.96.

TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Monday, August 4th. The biopharmaceutical company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.15). The company had revenue of $141.15 million for the quarter, compared to analysts’ expectations of $147.76 million. TG Therapeutics had a return on equity of 26.05% and a net margin of 13.31%.TG Therapeutics’s revenue for the quarter was up 92.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.04 earnings per share. TG Therapeutics has set its FY 2025 guidance at EPS. On average, sell-side analysts expect that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.